2,4-Dinitrophenol (DNP) is reported to cause rapid loss of weight, but unfortunately is associated with an unacceptably high rate of significant adverse effects. DNP is sold mostly over the internet under a number of different names as a weight loss/slimming aid.
2,4-DINITROPHENOL is a solid yellow crystals. Explosive when dry or with less than 15% water. The primary hazard is from blast of an instantaneous explosion and not flying projectiles and fragments. slightly soluble in water and soluble in ether and solutions of sodium or potassium hydroxide
The effect of 2,4-dinitrophenol (DNP) to increase metabolic rate has been known since the late 1800. In the early 1930s, DNP was widely used as a weight loss drug; however, enthusiasm for DNP therapy waned due to its low therapeutic index and serious toxicities, including hyperthermia, skin reactions, cataracts, and death.
The news isn't all bad as reported and clinically proven DNP can cause rapid fat loss, DNP treatment also improves glucose homeostasis and lower insulin levels in response to glucose challenge. ADDITIONALLY 2,4-dinitrophenol (DNP), protects neurons against neurodegeneration and enhances neural plasticity.
DNP SOUNDS GREAT UNTIL YOU STACK IT UP AGAINST FIT STACK
FIT STACK THE NEWEST GENERATION OF METABOLIC ENHANCERS
What happens when you combine SR 9009, GW-501516, Clen2.0
-Consider SR-9009 increases mitochondria size and the number of mitochondria
-Consider GW-501516 switches your cells preference to burning fats
-Consider Clen 2.0 liberates FAT cells into Free fatty acids
-Only thing left to do is the research
-SR9009 is an attractive performance-enhancing substances due to the REV-ERB agonist effect and thus circadian rhythm modulation activity. Although no pharmaceutical preparations are available yet, illicit use of SR9009 for doping purposes can be anticipated, especially since SR9009 is marketed in illicit products.
-Effects of SR9009 and SR9011 observed via in vitro and in vivo animal studies were increased basal oxygen consumption, decreased lipogenesis, cholesterol and bile acid synthesis in the liver, increased mitochondrial content, glucose and fatty acid oxidation in the skeletal muscle and decreased lipid storage in the white adipose tissue.
-The observed increase in energy expenditure and decrease in fat mass make the REV-ERB agonist SR9009 a promising drug candidates for the treatment of several metabolic disorders.
-SR 9009 suppresses post-MI mortality and improves cardiac function
-SR 9009 reduces infiltration of neutrophils and M1 macrophages into the infarcted myocardium.
-SR 9009 (REV-ERB) Agonists Block Autophagy in Cancer Cells
-GW-501516 ( PPARδ ) regulates muscle metabolism and reprograms muscle fibre types to enhance running endurance
-GW-501516 Increases muscle size fullness and pump
-GW501516 enhances specific consumption of fatty acids and reducing glucose utilization, Whereas training increases energy availability by promoting catabolism of proteins, and gluconeogenesis.
-GW501516 is a selective and high-affinity synthetic agonist of peroxisome proliferator-activated receptor β/δ (PPARβ/δ). This molecule promoted the inhibition of proliferation and apoptosis in few cancer cell lines.
-—GW501516 produced significant changes in HDL cholesterol, LDL cholesterol, apoA1, and apoB. Fewer very LDL and larger LDL support a transition toward less atherogenic lipoprotein profiles. These data are consistent with peroxisome proliferator-activated receptor-δ being a potentially important target for providing cardiovascular protection in metabolic syndrome-like patients.
( SALBUTAMOL, ALBUTEROL )
-Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Beta 2-Adrenoceptor agonists have been shown to increase rapidly lean body mass and reverse muscle wasting in several animal models of human illness.
-during the trial. In contrast, the strength of both quadriceps muscles increased significantly (12 +/- 3%) after 14 days on salbutamol, and remained elevated at 21 days. Whereas the strength of the hamstring muscles of the dominant leg significantly increased after 21 days on salbutamol (22 +/- 6%)
-Albuterol improves response to levodopa and increases skeletal muscle mass.
-Albuterol increased lipolysis in vitro and metabolic rate in humans, Albuterol treatment resulted in a trend for increased metabolic yet caffeine did not increase the effect of albuterol alone.
-However, the addition of caffeine to albuterol enhanced the treatment’s ability to increase lean body mass while decreasing fat mass without changing food intake, and deserves further exploration as a potential treatment for pediatric obesity.